Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges

Bibliography

• JEMAL A, MURRAY T, SAMUELS A et al: Cancer statistics, 2003. CA Cancer Chit. (2003) 53(1):5–26.
   PubMed Web of Science ®Google Scholar
• •Most recent data on cancer incidence, mortality, and survival in the US.
   Google Scholar
• SOLOWAY MS, CHODAK G, VOGELZANG NJ et al: Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology (1991) 37:46–51.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF, OSOBA D, STOCKLER MR et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. ?Chit. Oncol. (1996) 14:1756–1764.
   Google Scholar
• •First Phase III data to show the palliative value of chemotherapy in HRPC patients.
   Google Scholar
• OH WK, KANTOFF PW: Management of hormone refractory prostate cancer: current standards and future prospects. ?Ural. (1998) 160:1220–1229.
   Google Scholar
• KANTOFF PW, HALABI S, CONAWAY M etal.: Hydrocortisone with or withoutmitoxantrone in men with hormone- refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. ?Clin. Oncol. (1999) 17(8):2506–2513.
   Google Scholar
• EISENBERGER MA, SIMON R, O'DWYER PJ et al.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. ?Chit. Oncol. (1985) 3:827–841.
   Google Scholar
• YAGODA A, PETRYLAK D: Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer (1993) 71:1098–1109.
   PubMed Web of Science ®Google Scholar
• SMITH PH, BONO A, CALMS DA, SILVA F et al.: Some limitations of the radioisotope bone scan in patients with metastatic prostate cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer (1990) 66:1009–1016.
   Google Scholar
• BUBLEY GJ, CARDUCCI M, DAHUT Wetal.: Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. j Chit. Oncol. (1999) 17:3461–3467.
   Google Scholar
• ROTH BJ, YEAP BY, WILDING G etal.: Taxol in advanced, hormone refractory carcinoma of the prostate: a Phase II trial of the Eastern Cooperative Oncology Group. Cancer (1993) 72:2457–2360.
   Google Scholar
• TRIVEDI V, REDMAN B, FLAHERTY LE et al.: Weekly 1-hour infusion of paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer (2000) 89:431–436.
   PubMed Web of Science ®Google Scholar
• PICUS J, SCHULTZ M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone refractory prostate cancer: preliminary results. &min. Oncol. (1999) 26\(Suppl. 17):14–18.
   Google Scholar
• BERRY W ROHRBAUGH T: Phase II trial of single agent, weekly (wk) taxotere (t) in symptomatic, hormone-refractory prostate cancer (HRPC). American oncology resources clinical research task force. Proc. Am. Soc. Chit. amyl (1999) 18:335a.
   Google Scholar
• BEER TM, PIERCE WC, LOWE BA et al: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol. (2001) 12(9):1273–1279.
   PubMed Web of Science ®Google Scholar
• EKLOV S, NILSSON S, LARSON A et al: Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate (1992) 20:43–50.
   PubMed Web of Science ®Google Scholar
• SPEICHER LA, LAING N, BARONE LR et al.: Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Pharmacol. (1994) 46:866–872.
   Google Scholar
• YAGODA A, SMITH JA, SOLOWAY MS et al.: Phase II study of estramustine phosphate in advanced hormone refractory prostatic cancer with increasing prostate specific antigen levels. j Ural. (1991) 145:384A (Abstract).
   Google Scholar
• SPEICHER LA, BARONE L, TEW KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. (1992) 52:4433–4440.
   PubMed Web of Science ®Google Scholar
• KREIS W, BUDMAN DR, CALABRO A: Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br. J. Ural. (1997) 79:196–202.
   PubMedGoogle Scholar
• PIENTA KJ, NAIK H, LEHR JE: Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology (1996) 48:164–170.
   PubMedGoogle Scholar
• HUDES GR, NATHAN F, KHATER C et al.: Phase II trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. j Clin. Oncol. (1997) 15:3156–3163.
   PubMed Web of Science ®Google Scholar
• HUDES GR, MANOLA J, CONROY J, HABERMANN T, WILDING G: Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group. Proc. Am. Soc. Clin. Oncol. (2001) 20:175a (Abstract).
   Google Scholar
• PETRYLAK DP, MACARTHUR RB, O'CONNOR J etal.: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. j Chit. Oncol. (1999) 17(3):958–967.
   Google Scholar
• PETRYLAK DP, SHELTON GB, ENGLAND-OWEN C et al: Response and preliminary survival results of a Phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPC). Proc. Am. Soc. Clin. Oncol. (2000) 19:334a.
   Google Scholar
• ••This trial was the basis for the regimenselected for both the SWOG 9916 and ECOG 1899 trials.
   Google Scholar
• SAVARESE D, HALABI S, HARS V etal.:A Phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer. J. Clin. Oncol. (2001) 19:2509–2516.
   Google Scholar
• SINIBALDI VJ, CARDUCCI MA, MOORE-COOPER S, LAUFER M, ZAHURAK M, EISENBERGER MA: Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer (2002) 94:1457–1465.
   PubMed Web of Science ®Google Scholar
• COPUR MS, TARANTOLO SR, HAUKE R et al: Weekly estramustine, taxotere, and dexamethasone in patients with hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:347a.
   Google Scholar
• VAISHAMPAYAN U, FONTANA J, HUSSAIN M: An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer. Urology (2002) 60:1050–1054.
   PubMed Web of Science ®Google Scholar
• ATHANASIADIS A, TSAVDARIDIS D, ATHANASSIADES I et al.: Paclitaxel (p) and estramustine phosphate (EP) in patients with hormone refractory prostate cancer (HRPC): a Phase II study. Proc. Am. Soc. Chit. Oncol. (2001) 20:189A (Abstract).
   Google Scholar
• PIENTA KJ, REDMAN B, HUSSAIN M et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. jClin. Oncol. (1994) 12:2005–2012.
   PubMed Web of Science ®Google Scholar
• PIENTA KJ, REDMAN BG, BANDEKAR R et al.: A Phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology (1997) 50:401–406.
   PubMedGoogle Scholar
• DIMOPOULOS MA, PANOPAULOS C, BAMIA C et al: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology (1997) 50:754–758.
   PubMed Web of Science ®Google Scholar
• HUDES GR, GREENBERG R, KRIGEL RL etal.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. ?Chit. Oncol. (1992) 10:1754–1761.
   Google Scholar
• SEIDMAN AD, SCHER HI, PETRYLAK D et al.: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. ?Ural. (1992) 147:931–934.
   Google Scholar
• BRACARDA S, TONATO M, ROSI P et al: Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a Phase II study. Cancer (2000) 88:1438–1444.
   PubMed Web of Science ®Google Scholar
• HUDES G, EINHORN L, ROSS E et al:Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network Phase III trial. j Clin. Oncol. (1999) 17:3160–3166.
   PubMed Web of Science ®Google Scholar
• •Phase III data demonstrating some superiority for estramustine-based, antimicrotubule drug-combinations in HRPC.
   Google Scholar
• SMITH MR, KAUFMAN D, OH W et al:Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a Phase II study. Cancer (2000) 89(8):1824–1828.
   PubMed Web of Science ®Google Scholar
• SWEENEY CJ, MONACO FJ, JUNG SH etal.: A Phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann. Oncol. (Huntingt) (2002) 13:435–440.
   Google Scholar
• COLLEONI M, GRAIFF C, VICARIO G etal.: Phase II study of estramustine, oral etoposide and vinorelbine in hormone-refractory prostate cancer. Am. j Clin. Oncol. (1997) 20:383–386.
   Google Scholar
• ELLERHORST JA, TU SM, AMATO RJ etal.: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Chit. Cancer Res. (1997) 3:2371–2376.
   Google Scholar
• SMITH DC, ESPER P, STRAWDERMAN M et al: Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. I Clin. Oncol. (1999) 17:1664–1671.
   PubMed Web of Science ®Google Scholar
• KELLY WK, CURLEY T, SLOVIN S et al: Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer. j Chit. Oncol. (2001) 19:44–53.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GG, HULKA BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anti-Cancer Res. (1990) 10(5A):1307–1311.
   Google Scholar
• SKROWRONSKI RJ, PEEHL DM, FELDMAN D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cells. Cancer Endoctinol. (1993) 132(5):1952–1960.
   PubMed Web of Science ®Google Scholar
• MILLER GJ, STAPLETON GE, FERRAR JA etal.: The human prostatic carcinoma cell in LNCaP expresses biologically active, specific receptors for I-a, 25-dihydroxyvitamin D3. Cancer Res. (1992) 52(3):515–520.
   Google Scholar
• YU WD, MCELWAIN MC, MODZELEWSKI RA et al: Potentiation of 1,25 dihydroxyvitamin D3-mediated
   Google Scholar
• •• anti-tumor activity with dexamethasone. j Natl. Cancer Inst. (1998) 90:134–141.
   Google Scholar
• TRUMP DL, SERAFINE S, BRUFSKY A et al.: High dose calcitriol (1,25 (OH)2 vitamin D3) and dexamethasone in androgen independent prostate cancer (AIPC). Ann. Oncol. (2000) 12:337a.
   Google Scholar
• BEER TM, EILERS KM, GARZOTTO M et al.: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. j Clin. Oncol (2003) 21:123–128.
   PubMed Web of Science ®Google Scholar
• ••Important Phase II data of novelcombination of chemotherapy and a biological agents.
   Google Scholar
• FIGG WD, DAHUT W, DURAY P et al.: A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. (2001) 7:1888–1893.
   PubMed Web of Science ®Google Scholar
• DAHUT WL, ARLEN PM, GULLEY et al.: A randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Proc. Am. Soc. Oncol. (2002) 21:183a
   Google Scholar
• FIGG WD, ARLEN E GULLEY J et al.: A randomized Phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. &min Oncol. (2001) 28(4 Suppl. 15):62–66.
   Google Scholar
• SEPP-LORENZINO L, BALOG A, SU DS et al.: The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis. (1999) 2:41–52.
   PubMed Web of Science ®Google Scholar
• MEKHAIL T, HOLDEN S, PIERSON S et al.: A Phase I pharmacokinetic and biologic study of the novel epothilone BMS-310750 in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:408a.
   Google Scholar
• SMALETZ 0, KELLY WK, HORSE-GRANT D et al.: Epothilone B analogue (BMS-247550) with estramustine phosphate (EMP) in patients (pts) with progressive castrate-metastatic prostate cancer (pc). Proc. Am. Soc. Clin. Oncol. (2002) 21:732a.
   Google Scholar
• CHAMBERS AF, MATRISIAN L: Changing views of the role of matrix metalloproteinase in metastasis. j Nati Cancer Inst. (1997) 89:1260–1270.
   PubMed Web of Science ®Google Scholar
• KAHARI VM, SAARIALHO-KERE U: Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann. Med. (1999) 31:34–45.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, ECKHARDT SG: Development of matrix metalloproteinase inhibitors in cancer therapy. j Nati Cancer Inst. (2001) 93(3):178–193.
   PubMed Web of Science ®Google Scholar
• EISENBERGER MA, SINIBALDI V, LAUFER M et al.: Phase I/ + pharmacokinetic evaluation of marimastat in patients with advanced prostate cancer. Proc. Am. Soc. Chit. Oncol. (2000) 19:336.
   Google Scholar
• WILDING G, SMALL E, COLLIER M et al.: A Phase I pharmacokinetic evaluation of the matrix metalloproteinase (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract).
   Google Scholar
• AHMANN FR, SAAD E MERCIER R etal.: Interim results of a Phase III study of the matrix metalloproteinase inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc. Amer. Soc. Clin. Oncol. (2001) 20:692.
   Google Scholar
• BOISSIER S, MAGNETTO S, FRAPPART L et al.: Bisphosphanates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. (1997) 57:3890–3894.
   PubMed Web of Science ®Google Scholar
• FOURNIER P, BOISSIER S, FILLEUR S etal.: Bisphosphanates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. (2002) 62:6538–6544.
   Google Scholar
• BOSSIER S, FERRERAS M, PEYRUCHAUD 0 et al.: Bisphosphanates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastates. Cancer Res. (2000) 60(11):2949–2954.
   Google Scholar
• PELGER RC, HAMDY NA, ZWINDERMAN AH et al.: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone (1998) 22:403–408.
   PubMed Web of Science ®Google Scholar
• ADAMI S, MIAN M: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent results. Cancer Res. (1989) 116:67–72.
   PubMedGoogle Scholar
• STRANG P, NILSSON S, BRANDSTEDT S et al.: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anti-cancer Res. (1997) 17:4717–4721.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE, PUROHIT OP, VINHOLES JJ et al.: High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer (1997) 80:1686–1690.
   PubMed Web of Science ®Google Scholar
• CRESSWELL SM, ENGLISH PJ, HALL RR et al.: Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br. j Ural. (1995) 76:360–365.
   PubMedGoogle Scholar
• SAAD E GLEASON DM, MURRAY R et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. j Nati Cancer Inst. (2002) 94(19):1458–1468.
   PubMed Web of Science ®Google Scholar
• ••Phase III data confirming the importanceof zoledronic acid in reducing skeletal-related events in prostate cancer patients with bone metastases.
   Google Scholar
• WITTERS L, CRISPINO J, JAVEED M etal.: Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor. Proc. Am. Soc. OM. Oncol. (2002) 21:5b.
   Google Scholar
• PORTER AT, MCEWAN AJ, POWE JE et al.: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. Radiat. Oiled. Biol. Phys. (1993) 25:805–813.
   PubMed Web of Science ®Google Scholar
• MCEWAN AJ, AMYOTTE GA, MCGOWAN DG et al.: A retrospective analysis of the cost effectiveness of treatment with metastron in patients with prostate cancer metastatic to bone. Eur. Ural. (1994) 26\(Suppl. 1):26–31.
   Google Scholar
• QUILTY PM, KIRK D, BOLGER JJ et al.: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol. (1994) 31:33–40.
   PubMed Web of Science ®Google Scholar
• SERAFINI AN, HOUSTON SJ, RESCHE I et al.: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. j Clin. Oncol. (1998) 16:1574–1581.
   PubMed Web of Science ®Google Scholar
• SARTOR 0, QUICK D, REID R et al.: A double blind placebo-controlled study of 153-Samarium-EDTMP for palliation of bone pain in patients with hormone-refractory prostate cancer. Anna Meet. Am. Urol. Assoc. (1997) (Abstract 1252).
   Google Scholar
• KRAEBER-BODERE F, CAMPION L, ROUSSEAU C etal.: Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur. Nucl Med (2000) 27:1487–1493.
   Google Scholar
• FARHANGHI M, HOLMES RA, VOLKERT WA et al: Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl Med (1992) 33:1451–1458.
   PubMedGoogle Scholar
• TU SM, MILLIKAN RE, MENGISTU B et al.: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet (2001) 357:336–341.
   PubMed Web of Science ®Google Scholar
• AKERLEY W, BUTERA J, WEHBE et al: A multi-institutional, concurrent chemoradiation trial of strontium-89, estramustine and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer (2002) 94: 1654-1660.
   Google Scholar
• SHAH R, KOHLI M, JOHNSON D et al: A Phase I/II study of docetaxel, estramustine-phosphate and strontium-89 in metastatic hormone-refractory prostate cancer. Proc. Am. Soc. Chu. Oricol. (2002) 21:2457.
   Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al.: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Li. USA (1989) 86:2863–2867.
   PubMed Web of Science ®Google Scholar
• KOPETZ ES, NELSON JB, CARDUCCI MA: Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest. New Drugs (2002) 20:173–182.
   PubMed Web of Science ®Google Scholar
• NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med (1995) 1:944–949.
   PubMed Web of Science ®Google Scholar
• NELSON JB, CHAN-TACK K, HEDICAN SP et al: Endothelin-1 production and decreased endothelin-B receptor expression in advanced prostate cancer. Cancer Res. (1996) 56:663–668.
   PubMed Web of Science ®Google Scholar
• GOHJI K, KITAZAWA S, YAMASHITA K et al.: The expression of endothelin receptor A associated with prostate cancer progression. j Ural. (2001) 165(3):1033–1036.
   PubMedGoogle Scholar
• CARDUCCI MA, NELSON JB, BOWLING MK et al: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. j Chu. Duca (2002) 20(8):2171–2180.
   Google Scholar
• ••Phase I data providing impetus forPhase III studies of atrasentan.
   Google Scholar
• CARDUCCI MA, PADLEY RJ, BREUL J et al.: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, Phase II, placebo controlled trial. Chu. Duca (2003) 21:679–689.
   Google Scholar
• ••Phase II data providing impetus ofPhase III studies of atrasentan.
   Google Scholar
• SIMONS JW, MIKHAK B, CHANG JF et al: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59(20):5160–5168.
   PubMed Web of Science ®Google Scholar
• SIMONS J, NELSON W, NEMUNAITIS Jet al: Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Duca (2002) 21:183a.
   Google Scholar
• RODRIGUEZ R, SCHUUR ER, LIM HY, HENDERSON GA, SIMONS JW, HENDERSON DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559–2563.
   PubMed Web of Science ®Google Scholar
• ••Data providing basis for PSA oncolyticadenovirus.
   Google Scholar
• DEWEESE TL, VAN DER POEL H, LI S et al: A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. (2001) 61(207464–7472.
   Google Scholar
• ••Data suggesting bioactivity with responseusing PSA oncolytic adenovirus.
   Google Scholar
• CHEN Y, DEWEESE T, DILLEY J et al.: CN706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. (2001) 61:5453–5460.
   PubMed Web of Science ®Google Scholar
• YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59(17):4200–4203.
   PubMed Web of Science ®Google Scholar
• YU DC, CHEN Y, DILLEY J et al: Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. (2001) 61(2):517–525.
   PubMed Web of Science ®Google Scholar
• HWANG C, SANDA MG: Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Cun: Opirt. Mol. Ther. (1999) 1(4):471–479.
   PubMed Web of Science ®Google Scholar
• BANDER NH, NANUS D, GOLDSMITHS etal.: Phase I trial of humanized monoclonal antibody (mAb) to prostate specific membrane antigen/extracellular domain (PSMAext). Proc. Amer. Soc. Chu. Duca (2001) 20:722.
   Google Scholar
• BANDER NH, TRABULSI EJ, YAO D etal.: Phase I radioimmunotherapy (PIT) trials of humanized monoclonal antibody (MAB) J591 to the extracellular domain of prostate specific membrane (PSMAext) radiolabeled with 9°Yttium (90Y) or inLutetuim 0770 in advanced prostate cancer (PCA). Proc. Am. Soc. Chu. Duca (2002) 21:5a.
   Google Scholar
• SMALL EJ, FRATESI P, REESE DM et al: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. j Chu. Duca (2000) 18(23):3879–3882.
   Google Scholar